Sustainability

MSD for Mothers: Expanding access to quality maternal care

More than a decade of strategic partnerships, private sector innovation and data-driven impact to help create a world where no woman has to die while giving life

May 7, 2024

Share this article

.st0{fill:#00857C;}

article hero thumbnail

According to the latest data from the World Health Organization, a maternal death occurs almost every two minutes. Nearly 95% of all maternal deaths occur in low- and lower-middle income countries, and most could have been prevented.

If we don’t do more, mothers, daughters and granddaughters will continue to lose their lives. And their loss will impact many.

mother and baby smiling at each other

The birth of MSD for Mothers

In response to this crisis, our company created MSD for Mothers, a $650 million global initiative to help create a world where no woman has to die while giving life.

“By helping address one of the oldest and most preventable global health tragedies, we believe MSD for Mothers will have an important impact on society,” said Ken Frazier, MSD’s then-chairman and CEO, as he introduced this program at the United Nations General Assembly (UNGA) in 2011.

MSD for Mothers began its mission by joining the UN and collaborators around the globe to apply its scientific and business expertise to help save women’s lives, aligned with Sustainable Development Goal 3.1 to reduce the global maternal mortality ratio to less than 70 per 100,000 births by 2030. Achieving this goal would save the lives of approximately 1.4 million women between 2016 and 2030.

A sustainable model to make a difference for generations

Focused on advancing high-quality maternity care, harnessing innovations for maternal health and catalyzing solutions that respond to local needs, MSD for Mothers aims to make a difference for women and their communities now and in the future.

A man holding a picture of a loved one in a church

Women around the world die during pregnancy and childbirth for a variety of reasons, including a lack of medical supplies or inadequate health care services to address complications. Other times, it’s due to delays in seeking care or difficulties getting to a medical facility. Sometimes, women can’t afford to pay for health services. And often, women do not have information about or access to contraceptives to help them make their own decisions about whether or not to become pregnant.

MSD for Mothers takes a holistic approach to addressing the many factors that impact maternal health. It collaborates across sectors — working with governments, nongovernmental organizations, patient groups, professional associations, entrepreneurs, UN agencies, research institutions, businesses and even other pharmaceutical companies. The initiative also supports innovations across digital, finance, products and policy, and strives to leverage the private sector for public good. Engaging local stakeholders in designing, implementing and evaluating solutions plays an important role in creating sustainable improvements.

"We believe investing in maternal health care is a pathway to better health for all."

Jacquelyn Caglia

Director of learning, communications and U.S. programs, MSD for Mothers

“Working closely with our collaborators, we’re taking a holisitic approach to address inequities that impact maternal health, reflecting our company’s commitment to expanding access to health and advancing health equity around the world,” said Jacquelyn Caglia, director of learning, communications and U.S. programs, MSD for Mothers. “The impact we’ve made reflects our team’s dedication and the incredible efforts of community-based organizations globally. There’s still much to be done, which is why we’re focused on building on our learnings and scaling our impact.”

Making an impact and the ripple effect

MSD for mothers has worked alongside more than 165 grantees and collaborators in more than 70 countries to find, test, scale and sustain solutions to reduce maternal mortality.

“Our programs directly reach women and health systems. Since 2011, we’ve reached more than 30 million women globally, helping them have healthier pregnancies and safer childbirths through programs promoting high-quality and respectful care — surpassing our goal of reaching 25 million women by 2025,” said Mark Allen, director of global programs & strategic partnerships, MSD for Mothers.

160M+

people reached through improved access to quality facilities

30M+

women with access to programs supporting safe, high quality, respectful care

397,000

providers with improved training

And, research shows that investing in maternal health can have a ripple effect. Better maternal health care is a pathway to a lifetime of benefits, both for a woman’s own health and prosperity as well as that of her children, family, community and nation.

Infants are 15 times more likely to survive

Children are 10 times more likely to finish school

Millions of dollars are contributed by women to the economy

“When we invest in maternal health, we ensure that hundreds of thousands of women survive pregnancy and childbirth. When that happens, newborns are more likely to survive, children are more likely to stay in school, women are able to make invaluable contributions to their communities and the workforce, health systems are stronger and nations’ economies grow,” explains Allen. “We call this the ‘Mom Effect.'”

And, that’s an important impact on society for generations to come.

Explore our progress over the past 10+ years


View by:
Ken Frazier visiting with a patient

2011

Ken Frazier announces launch of MSD for Mothers 

Pregnant woman in the garden

MSD for Mothers and PATH collaborate to identify game-changing technologies

Spearheaded by top scientists from MSD for Mothers and the global nonprofit, PATH, this unique alliance evaluated promising technologies that address the two leading causes of maternal mortality — post-partum hemorrhage (PPH) and preeclampsia — as well as family planning. This collaboration surfaced the ideas of focusing on a heat-stable uterotonic (carbetocin) to address excessive bleeding during childbirth and optimizing magnesium sulfate administration for pregnant women with preeclampsia – two initiatives that we continue to fund today.

2012

MSD for Mothers joins new global partnership — Saving Mothers, Giving Life

This public-private partnership focuses on helping mothers during labor, delivery and the first 24 hours following birth, when an estimated two-thirds of maternal deaths and almost half of infant deaths occur. With a pledge of more than $200 million, the partnership began with programs in Uganda and Zambia, where maternal mortality rates are disproportionately high.

mother holding her baby
Pregnant woman in India and a child in the background

2013

MSD for Mothers launches $10 million initiative in India

This initiative to improve access to maternal health services will reach nearly 500,000 pregnant women in Uttar Pradesh, Rajasthan and Jharkhand — all areas with high rates of maternal deaths.

pregnant woman being examined by a nurse

Global health, development and business leaders announce new innovative financing partnership

This partnership leverages private sector funding to speed up delivery and access to life-saving health supplies, such as contraceptives, bed nets, and medicines to those in need. Through Pledge Guarantee for Health (PGH), this new financing mechanism helps increase the impact of each dollar of donor funding and ultimately improve health care access and outcomes for the millions who are helped by foreign aid.

Through the partnership, MSD and other private sector suppliers step up to provide up-front price discounts to aid recipients who utilize PGH to purchase their life-saving health supplies.

woman holding baby smiling

MSD for Mothers launches programs in the U.S.

The maternal mortality rate in the U.S. has nearly doubled since 1990. More than 50,000 women a year — one every 10 minutes — nearly die from severe complications they experience during pregnancy or childbirth. With an initial commitment of $6 million, these programs aim to enhance community care initiatives for high-risk women before, during and after childbirth; implement standard approaches to address obstetric emergencies; and strengthen data collection and reviews to better understand why maternal deaths occur and how to improve practices and patient care.

3 women holding babies and one pregnant woman in Kenya

2014

MSD, Ferring Pharmaceuticals and WHO announce collaboration to prevent excessive bleeding in women after childbirth

MSD, Ferring Pharmaceuticals and WHO collaborate to advance a new, proprietary formulation of carbetocin to prevent excessive bleeding in women after childbirth. A primary benefit of carbetocin is its ability to remain stable at room temperature, even in hot and tropical climates, unlike oxytocin, the standard medicine administered for the prevention of PPH. Oxytocin is temperature-sensitive and requires sustained cold distribution and storage, which is difficult to achieve in many of these areas of high maternal mortality.

Mother holds child on her lap while holding up a cell phone with a text message on it and a test in the other hand

2015

MSD for Mothers explores digital technologies to mobilize maternal health 

MSD for Mothers commits resources to invent or enhance existing solutions to tackle some of the most critical obstacles standing in the way of delivering quality maternity care and contraceptive services in low- and middle-income countries. This commitment leads to a new wave of smart, innovative apps and digital platforms – like the Safe Delivery App, mDoc, Project iDeliver, AskNivi, MomCare, Together for Her Health, among others.

mother and baby at the market

MSD and MSD for Mothers help advance a new set of UN global goals

The Sustainable Development Goals (SDGs) are formally adopted at the 70th UNGA. They represent the international community’s aspirations for improving the lives of the world’s poorest people by 2030.

mother holding her new baby

MSD for Mothers has now reached 5 million women worldwide through its programs

MSD for mamas care packages

2016

Employees across the globe join the fight to end maternal mortality

Employee volunteers participate in activities such as assembling post-natal kits for soon-to-be mothers in Uganda as a means of encouraging them to seek care to support healthy pregnancies and deliveries. The kits include essential supplies to aid the health and safety of a mother and newborn after birth. This activity, among others, become annual events where employees can help amplify our impact. 

MSD for Mothers’ collaborators complete their first maternity waiting home in Zambia

Maternity waiting homes — residences located near health facilities where pregnant women can stay before they go into labor — can make all the difference for pregnant women in rural Zambia, where the distance between home and a health facility can be a matter of life and death.

two men working on a brick house
Nurse caring for a pregnant woman

2017

MSD for Mothers teams up with stakeholders across India to launch Manyata

MSD for Mothers, Jhpiego India and the Federation of Obstetric and Gynecological Societies of India partnered to launch Manyata – an ambitious agenda to improve quality of maternity and newborn care services in private facilities by training doctors, nursing and administrative staff on essential clinical, facility and patient care protocols in India.

a nurse helping patients fill out paper work

MSD for Mothers commits $10 million and business expertise to the Global Financing Facility

In support of the UN Secretary-General’s Every Woman Every Child strategy to improve maternal and child health in low- and lower-middle-income countries, the goal is to prevent an estimated 3.8 million maternal deaths, 101 million child deaths and 21 million stillbirths by 2030. MSD is the first private sector investor and helped bring other private sector investors to the table.

female doctor working with nurse

MSD for Mothers launches the world’s first maternal and newborn health development bond with public and private sector collaborators

The Utkrisht Development Impact Bond leverages private investor capital to incentivize private maternity providers in Rajasthan, India to improve the quality of care they deliver. Interventions will reach up to 600,000 pregnant women with improved care during delivery and could lead up to 10,000 lives being saved over a five-year period. 

Female doctor on her rounds at hospital in India

2018

Ferring Pharmaceuticals and MSD announce completion of carbetocin clinical trial, the largest clinical trial ever conducted in postpartum hemorrhage

The trial of heat-stable carbetocin showed it to be as safe and effective as oxytocin in preventing postpartum hemorrhage, the largest direct cause of maternal death. The trial included nearly 30,000 women from 10 countries.

“This has the potential to change the paradigm in how we save more mothers from dying during childbirth,” said Dr. Julie L. Gerberding, MSD’s then-chief patient officer.

two pregnant women touching bellies

MSD announces new U.S. initiative — Safer Childbirth Cities

Through this initiative, MSD for Mothers will provide grants to help cities with poor maternal health outcomes develop and implement creative, multi-sector solutions to save women’s lives, improve maternal health and narrow racial disparities.

Woman kissing her child in home in Romania

MSD for Mothers publishes first research compendium to advance collective understanding of maternal mortality

The research compendium, Evidence for Impact, collates actionable and real-time evidence about what works and what doesn’t to expand knowledge that will help encourage greater investment in women’s health. MSD for Mothers publishes a second compendium in 2020.
Mother holding baby alongside two other young children - in Romania

2019

MSD for Mothers has now reached 10 million women worldwide through its programs

happy couple with their baby

The MOMs (Maternal Outcomes Matters) Initiative launched

A partnership between MSD for Mothers, the U.S. International Development Finance Corporation, Credit Suisse and USAID to stimulate, advance and scale innovations that contribute to a healthy pregnancy and safe childbirth. It will invest $50M in local businesses that are working to improve maternal health in regions of the world where high rates of women are dying from pregnancy and childbirth. (Photo credit: LifeBank)

Pregnant belly next to the words "Hear her concerns" for the National Center for Chronic Disease Prevention and Health Promotion, Division of Reproductive Health

2020

MSD for Mothers provides funding to help support the CDC’s new maternal health communication campaign, Hear Her

Hear Her brings attention to maternal mortality and provides support to pregnant and postpartum women to speak up when something doesn’t feel right.

Woman nurse taking a pregnant woman's blood pressure

MSD commits $3M to address maternal health needs during COVID-19 pandemic

2021

MSD announces fifth round of global grants to tackle maternal mortality and promote health equity worldwide

MSD for Mothers supports the corporate grant program which enables MSD offices around the world to aid nongovernmental organizations that are improving maternal health. The program responds to local women’s needs, focusing on how resources can increase health equity in maternity care and support.

MSD announces additional $150M investment through 2025 to help end maternal mortality inequities, building on the $500M commitment made in 2011

This investment comes at a pivotal time for the global health community as the COVID-19 pandemic continues to stretch health systems, disrupting networks of care that support healthy pregnancies and safe childbirth.

Pregnant woman and her mother in hospital in India

2022

pregnant woman sitting on a bed

MSD for Mothers launches Strengthening Systems for Safer Childbirth Coalitions

This global initiative is supporting locally driven solutions with coalitions across India, Kenya, Nigeria and Sierra Leone. The coalitions lead activities to advance health equity by improving access to high-quality maternal health care for underserved or underrepresented groups.

2023

MSD for Mothers debuts new report examining how transformational impact can be made in maternal health

The report highlights six social investments whose solutions have demonstrated transformational impact on maternal health in different contexts — each with funding from MSD for Mothers. Learn more about the report.

Women and children
mother and son smiling and eating

MSD for Mothers supports organizations in Latin America

With a sixth round of global grants, MSD for Mothers supports organizations in Latin America, where wide disparities in maternal health outcomes persist. Through the grants, we aim to reach 135,000 women throughout Brazil, Colombia, Dominican Republic, Ecuador and Mexico.

2024

MSD for Mothers has reached more than 30 million women around the world

Through programs promoting safe, high-quality, respectful care, MSD for Mothers has now reached more than 30 million women, surpassing its goal of reaching 25 million women by 2025. Learn more

woman holding baby

New grants help women in southeastern Europe

Latest round of global grants supports UNICEF through innovative projects designed to meet the unique local needs of women in Bulgaria and Serbia. Learn more

We believe solutions to end maternal mortality and improve the quality of maternity care should be rooted in women’s voices and experiences

Patients

Podcast: A candid conversation about diversity in clinical trials 

Hear a patient and a doctor share why they want more people involved in medical studies

May 2, 2024

Share this article

.st0{fill:#00857C;}

article hero thumbnail

Clinical trials are an important part of helping to ensure new medicines are safe and effective. Yet a lack of awareness and feelings of hesitancy about joining one persist. 

Some people are uncertain about medical research due to past studies like the Tuskegee Experiment, when Black men were denied treatment for syphilis in the 1930s. Today, many are cautious when receiving advice from members of the medical community, including their doctors.  

Euvon Jones — a motivational artist, proud father and husband and a former clinical trial participant — hadn’t thought much about clinical trials before his diagnosis with prostate cancer, but he eventually decided to participate in a study to advance knowledge of the condition not only for himself but also for his community.

Listen to the podcast

Read the transcript

In this podcast, Jones joined Adrelia Allen, executive director of clinical trial patient diversity at our company, and Dr. Renee Matthews, director of live programming and production at BlackDoctor.org, to share the factors that impacted his decision to participate in a clinical trial and how that experience changed his perspective on medical research.

Jones said it’s hard to trust the process if you don’t trust your health care provider or the person recommending a clinical trial. “Good information might be provided, but you have to trust that the information is good for you,” he said. 

Additionally, Matthews discussed how misinformation perpetuates stigma around clinical trials and the work that her organization is doing to help instill confidence in people who are considering participating in clinical trials.  

Learn more about how we’re prioritizing diversity in clinical trials and why it’s so important.

Innovation

A new foundation for future talent

We’re partnering with America’s largest HBCU to launch a collaborative biotechnology learning center

May 2, 2024

Share this article

.st0{fill:#00857C;}

article hero thumbnail

Building the workforce of tomorrow means investing in the students of today. That’s why we’ve partnered with North Carolina Agricultural and Technical State University (N.C. A&T) — the largest historically Black college and university in the U.S. — to launch the MSD Biotechnology Learning Center.

“We’re pleased to launch this new collaboration with an institution that precisely aligns to our company priorities to invest in the growth and delivery of innovative health solutions and strong values around diversity and inclusion,” said Sanat Chattopadhyay, executive vice president and president, MSD Manufacturing Division. “Together we can fuel the growth of talent for our company and the biotechnology industry overall.”

Located in the home state of our Durham and Wilson manufacturing sites, the 4,025 square-foot facility will enhance academic programming and training for biotechnology careers for N.C. A&T students and provide advanced discovery opportunities through its classroom space, process laboratory and state-of-the-art biopharmaceutical manufacturing equipment.

“This collaboration signifies a union between academia and industry, and a commitment to excellence, innovation and the advancement of scientific knowledge,” said Tonya Smith-Jackson, Ph.D., provost and executive vice chancellor of academic affairs for N.C. A&T.

MMD-NCAT-aerial

The collaboration also signifies an investment in the community’s future by expanding local and statewide bioeconomy initiatives. It’ll also help to diversify talent and recruitment opportunities for our company and offer vaccine manufacturing process training for new and existing employees. 

“The MSD Biotechnology Learning Center will provide opportunities for N.C. A&T students to look inside the biopharmaceutical industry and understand what a career in this space looks like. Through our joint initiative with N.C. A&T, we’re developing new and innovative ways to build a pipeline of talent here in North Carolina and beyond.” 

  • Amanda Taylor
    Vice president and Durham plant manager
Innovation

Our Q1 2024 earnings report

April 25, 2024

Share this article

.st0{fill:#00857C;}

article hero thumbnail

MSD’s Q1 2024 results reflect continued strong growth in oncology and vaccines. Our company announced Q1 worldwide sales of $15.8 billion, an increase of 9% from Q1 2023.

“We have begun 2024 with continuing momentum in our business. We are harnessing the power of innovation to advance our deep pipeline and are maximizing the impact of our broad commercial portfolio for the benefit of patients,” said Rob Davis, chairman and chief executive officer. “We drove strong growth across key therapeutic areas, executed strategic business development, and in the U.S., we are now launching WINREVAIR, a significant new product in the cardiometabolic space for adults with pulmonary arterial hypertension, a progressive and debilitating disease. We have important opportunities ahead of us across all areas of our business, and we are highly focused on realizing them.”

MSD anticipates full-year 2024 worldwide sales to be between $63.1 billion and $64.3 billion.

Take a look at the infographic below for more details on Q1 2024 results.

Download infographic

Q1 Financial results infographic
Innovation

Humans, animals and the environment – our health is all connected

Why the One Health approach is important now more than ever

April 15, 2024

Share this article

.st0{fill:#00857C;}

article hero thumbnail

The health of humans, animals and the environment are all interconnected. When the health of one is at risk, the health of all may be at risk.   

We see it in diseases transferred between animals or insects and humans (called zoonotic and vector-borne diseases) such as rabies, Lyme disease, West Nile virus, swine flu and Ebola, among others. We also see it in the growing threat from antimicrobial resistance (AMR), which occurs when bacteria mutate in ways that make the medicines (antimicrobials) used to treat infections ineffective, or when these medicines are used inappropriately to treat viral infections. Or, in diseases in food-producing animals, jeopardizing global food security.

Our increasing vulnerability to such new health challenges has led to a focus on “One Health” — an integrated approach to addressing human, animal and environmental health for the benefit of all.

What is One Health?

One Health is the collaborative approach across multiple disciplines — working locally, regionally, nationally and globally — to prevent, detect and respond to health issues at the interfaces between humans, animals and the environment.

illustration of group of people

It requires collaboration among doctors, veterinarians, nurses, public health practitioners, epidemiologists, agricultural workers, ecologists, wildlife experts, and industry as well as policymakers, communities and even pet owners.

“No one person, organization or sector can address these issues alone. Identifying and responding to growing health challenges requires teamwork,” says Holger Lehmann, DVM, Ph.D., VP, pharmaceuticals research and development, MSD Animal Health.

But what has led to these increasing population health threats?

Why are we more vulnerable to new health challenges?

Society has undergone major changes over the past century. While technology, increased mobility, industrialization, urbanization and globalization have advanced human, animal and environmental health in many ways, they’ve also made us more vulnerable to new health challenges.

For example, according to the Centers for Disease Control and Prevention, every year, millions of people and animals around the world are affected by zoonotic diseases. Scientists estimate that around 60% of emerging infectious diseases that are reported globally come from animals, both wild and domestic. Over 30 new human pathogens have been detected in the last 3 decades, 75% of which have originated in animals.

They can be spread in a number of ways, including direct or indirect contact, vector-borne, foodborne or waterborne. In fact, foodborne pathogens cause millions of cases of sporadic illness and chronic complications, as well as large and challenging outbreaks in many countries and between countries.

In addition, increased exposure to new viruses/bacteria combined with excessive and/or inappropriate use of medicines is causing a rise in AMR. Worldwide, an estimated 4.95 million people died with drug-resistant bacterial infections in 2019, and 1.27 million of these deaths were directly caused by antimicrobial resistance (AMR).

Three main factors are fueling these population health threats, increasing the probability and speed of spreading diseases. They are:

Changes in climate and land use

Deforestation and other disruptions in environmental conditions can provide new opportunities for diseases to develop.

Exponential population growth and expansion into previously uninhabited areas

More people are living in close connection to their companion animals, and in some cases, closer to wild and domestic animals.

Increased international mobility

People, animals and animal products are moving more frequently, easily and widely than ever before.

Our commitment to One Health

With deep expertise in both human and animal health and a commitment to our shared environment, our company is well-positioned to be a leader in the One Health approach.

“We recognize the issues — such as zoonotic and infectious diseases and food safety and security — are interrelated,” says Ian Tarpey, Ph.D., VP, biological research and development, MSD Animal Health. “Our Animal Health and Human Health teams will continue to collaborate to discover and develop preventative solutions for existing and emerging diseases in animals and people.”

Our One Health approach focuses on many areas, including:

icon
Disease prevention

We remain focused on discovering and developing vaccines and technologies to help prevent both human and animal diseases.

icon
Surveillance and monitoring

We’re committed to advocating for and participating in scientifically based surveillance monitoring systems to better understand, track and predict health-related issues.

icon
Respecting our environment

We support science-based, environmentally sound international and national programs to address the challenges to environmental health.

icon
Innovation

Our human and animal health research laboratories collaborate in antimicrobial and vaccine research in many ways including sharing enabling technologies, expertise and evaluation of external opportunities. We’re also investing and developing predictive, monitoring and diagnostic technologies to help animal caretakers make data-driven evaluations of an animal’s health status and optimize their animals’ health and well-being.

icon
Stewardship of essential medicines

We’re playing a leading role in addressing AMR by not only discovering and developing medicines and vaccines to treat and prevent infectious diseases in humans and animals but also supporting responsible use of these products.

icon
Safe and sustainable food supply

We continue to work on developing vaccines and other tools to prevent animal disease to ensure a safe, nutritious, sustainable food supply, and we’ve implemented surveillance initiatives to enable more accurate risk profiling, early disease detection and individualized diagnosis/treatment decisions in livestock.

Corgi and cat running in field

The science of healthier animals

We build strong partnerships in an effort to improve the health of animals around the world, and approach our work with a deep sense of responsibility — to our customers, consumers, animals, society and the planet.

Our work to promote optimal health continues

“One Health recognizes the interconnectedness of human, animal and environmental health, acknowledging that the well-being of each is intricately linked. By embracing a collaborative approach, we can effectively address the complex challenges and promote optimal health for both humans and animals.”

– Dr. Jenelle Krishnamoorthy, VP, global public policy

Innovation

Taking on Zaire ebolavirus

How science and innovation fuel our efforts to help combat a rare but potentially deadly disease

April 11, 2024

Share this article

.st0{fill:#00857C;}

article hero thumbnail

Patients inspire us to pursue the best science in our inventions and everything we do. Every innovation has the potential to help build a healthier, more hopeful future for people everywhere — which means taking on some of today’s global health challenges, including Ebola.

Leading the effort to combat Zaire ebolavirus

Our company is a health care leader in the fight against Zaire ebolavirus. Along with external collaborators from all sectors, our scientists are at the forefront of the response to outbreaks of this potentially deadly disease as we continue to help address this global health challenge. Zaire ebolavirus has had a devastating impact on the world and has proved itself to be a potentially deadly and contagious disease, with a survival rate of 50%. While there are six identified Ebola virus species, the Zaire ebolavirus strain has been the leading cause of outbreaks over the last 20 years.

Global public health preparedness against future Zaire ebolavirus outbreaks requires advanced planning, system readiness for rapid deployment and collaboration and partnership between public and private entities around the world. Our partnerships with the World Health Organization (WHO) and other health partners around the globe are a crucial component of our commitment to helping save and improve lives.

“We take Zaire ebolavirus outbreaks very seriously and act with the utmost urgency to support response efforts,” said Rachael Bonawitz, clinical director, clinical research vaccines. “Our teams are dedicated to supporting the frontline workers whose brave actions are critical in outbreak response efforts.”

In 2021, we established an agreement with UNICEF to create the world’s first global Ebola Zaire stockpile, the result of breakthrough innovation and collaboration with four leading international health and humanitarian organizations across the world. The global stockpile offers a critical, rapid-response tool.

“It has been our honor to collaborate with WHO, Gavi, UNICEF, the U.S. government and many others in supporting outbreak preparedness and response efforts,” said Drew Otoo, president of global vaccines. “Through these collaborations, we demonstrate what’s possible when partners come together to pursue a common purpose for patients.”

This level of collaboration continues to be needed for Zaire ebolavirus and other diseases. We remain committed to working in collaboration with global and local health partners to support current and future outbreak response efforts.

Our people

How employees with careers in nursing are critical at MSD

Nurses' clinical expertise and patient experience provide valuable insight across our company

April 10, 2024

Share this article

.st0{fill:#00857C;}

article hero thumbnail

Nurses do vital work every day. The care they provide makes a profound difference in the lives of patients and their families. And that’s why employees with careers in nursing are critical at MSD.

Esther Smith-Howell, associate director, outcomes research, said her nursing background provides her with valuable experience she applies as a business scientist.

“I understand patients’ concerns and questions related to medications and care, their need for education and information, the social context that may affect their ability to access and pay for medications and care,” said Smith-Howell. “It helps me think holistically about research and patients.”

article quote image

"Integrating the patient perspective into solving scientific research problems is critical for successful patient outcomes."

— Esther Smith-Howell, Ph.D., MSHP, R.N.

Associate director, outcomes research, health care delivery research

A sincere desire to help patients

From product safety and labeling to marketing, clinical operations and medical affairs, we employ hundreds of registered nurses in non-clinical positions.

“Nurses are a valuable resource to our company in terms of their real-world patient experience, clinical expertise and talent,” said Mary Elmer, executive director, patient innovation & engagement, and a nurse herself. “They bring important perspectives to help inform our business.”

article quote image

"Nurses share a special bond. There's true camaraderie between us fueled by a sincere desire to help patients."

Mary Elmer, MSN, CRNP

Executive director, patient innovation & engagement

Steve Morin’s varied nursing experiences working directly with patients help inform his current role as director of regulatory policy. He’s served as a bone marrow transplant nurse in a hospital and a research nurse in clinical trials and held other nursing roles where he worked with a number of underserved populations from around the world.

“These experiences allowed me to see health from a global perspective, and I use that background now as I advocate for regulatory policies that will help improve patient outcomes.”

  • Steve Morin, MSHE, BSN
    Director, regulatory policy
Steve Morin

Nurses at MSD are critical to our work

The nurses’ diverse backgrounds and skillsets — surgical, oncology, primary care, pediatrics, among others — also allow for valuable insight overall and targeted support when needed in a specific area of focus.

Here are four ways employees use their nursing expertise to make clinical and non-clinical impact:

Drug delivery development

Providing input on early design models for our product teams to create user-friendly devices as well as easy-to-understand accompanying patient education materials.

Package design

Supporting human factor testing, which focuses on the interactions between people and the product, by providing perspective on the end-user experience of patients and the health care professionals who give our products to patients.

Communications materials

Providing personal and professional perspectives, including how patients and their families digest health information, cultural sensitivities, and other insights, so we deliver health literate information that is clear for people who use our products.

Clinical support

Mobilizing teams of nurses to assist our U.S. employee health department, including stepping away from their non-clinical day jobs to provide critical support and help prevent disruption in business activities.

Our colleagues share their thoughts on being nurses at MSD:

Emma Mason
Meet Emma Mason

Associate director, patient innovation and engagement

Jo Goldie
Meet Jo Goldie

Associate director, scientific engagement lead GU oncology

Meet Susanne Rodholm

Clinical operations manager, global clinical trial operations

Kathy McKeon
Meet Kathy McKeon

Senior corporate account executive

Dr. Lisa Lea
Meet Dr. Lisa Lea

Director, patient innovation and engagement

Cynthia Thompson
Meet Cynthia Thompson

Oncology sales representative, women’s health

Innovation

How MSD scientists are driving next-generation cancer research

Our scientists are accelerating research by looking to improve anti-tumor immune response, targeting specific cancer cells and helping inhibit cancer growth

April 4, 2024

Share this article

.st0{fill:#00857C;}

article hero thumbnail

In recent decades, our improved understanding of cancer has illuminated that we cannot treat all cancers as one disease — scientists have classified hundreds of types and found a myriad of genetic drivers underlying them. This means, just as cancer isn’t one disease, there cannot be just one way to treat all cancers.

“We’ve witnessed dramatic progress in how we treat a wide range of cancers, and our work at MSD has been foundational in how we treat metastatic disease, or cancer that has spread.”

  • Dr. Jane Healy
    Vice president and head of oncology early development, MSD Research Laboratories

“This is just the tip of the iceberg. These advancements are helping to fuel the next generation of discoveries and drive progress in the way we care for people with all stages of cancer. We must push research forward that supports early discoveries and novel innovations to advance the future of cancer research,” Healy said.

Driving research toward treating certain cancers earlier

With the ultimate goal of providing patients with the greatest chance for survival, our researchers are building a broad clinical development program focused on treating certain cancers at earlier stages.

“Expanding our research efforts into earlier stages of disease remains a top priority,” said Healy. “We’re pursuing research where we have the greatest potential to make a significant impact in helping reduce the risk of recurrence and improving survival.”

A robust pipeline of diverse approaches to advanced and earlier stages of cancer

In addition to driving research in earlier stages of cancer, Healy and her colleagues are investigating multiple mechanisms and modalities that may have the potential to address cancer in innovative ways. Through our own research and external collaborations, we’ve developed a robust pipeline that encompasses diverse approaches to treating advanced and earlier stages of cancer across more than 20 novel mechanisms, including:

  • Boosting anti-tumor immune responses: Learnings from recent advancements in cancer care have informed a more focused approach to research. Now, we’re investigating foundational cancer treatments combined with negative immune regulators that play different roles in adjusting the immune response.

    We’re also exploring individualized neoantigen therapies, a growing area of research focused on sharpening the immune response against a person’s own tumor by developing a therapy unique to their tumor’s mutation.
  • Tissue-specific targeting of chemotherapy to increase cancer cell sensitivity to immune responses: While chemotherapy remains an important treatment option, our scientists are exploring how antibody-drug conjugates (ADCs), with novel chemotherapy-like payloads, can be used as a more targeted approach to deliver chemotherapy.

    Similarly, we’re pursuing research that enhances the ability of T cells to recognize and attack tumors.
  • Impacting pathways that can drive cancer growth: We’ve identified opportunities for the direct targeting of cancer cell vulnerabilities and transcription factors that were previously considered untreatable. By designing therapeutic candidates that inhibit or degrade proteins and genes implicated in cancer pathways, we’re evaluating new ways to help address rare and difficult-to-treat cancers that currently have limited treatment options.

“We’re committed to investing in novel research where scientific opportunity and medical need converge.”

  • Dr. David Weinstock
    Vice president of discovery oncology, MSD Research Laboratories

“These key areas of research are the cornerstones of our broad and diverse pipeline, with more than 2,250 ongoing clinical trials, which include more than 1,600 trials evaluating combination regimens. We remain dedicated to discovering new ways to fight this disease and optimizing existing approaches — all while continuing to lead in supporting the next generation of cancer research,” said Weinstock.

Gloved hands work on labs

Learn more about our oncology pipeline

Innovation

In our commitment to R&D, the numbers speak for themselves

We follow the science where we can make the greatest difference

March 7, 2024

Share this article

.st0{fill:#00857C;}

article hero thumbnail

Our scientists are revolutionizing how we discover and develop medicines and vaccines to address unmet medical needs, focused on innovating in oncology, vaccines, infectious diseases, cardio-metabolic disorders, immunology and neuroscience

With a science-led but portfolio-driven approach to our pipeline, we’re harnessing new technologies to accelerate the drug discovery process as we use the power of leading-edge science to save and improve the lives of humans and animals around the world. And, we’re continuing to invest in research and discovery efforts, like breaking new ground in London and uniting research and manufacturing to help patients faster in Ireland.

Here’s a look at how we got there:

2023 by the numbers

Scientists pose in lab with crossed arms

$30.5 billion

Our research and development investment

Scientist working with chemicals

21,800

Employees driving our research activities

Scientist studies in lab

1,400+

Publications by our scientists in peer-reviewed journals

Woman listens intently to her doctor

100,000+

Patients enrolled in our clinical trials at more than 21,000+ sites worldwide

Child sits with doctor

50+

Countries around the world where we are conducting clinical trials

Scientist works with petri dish

330+

Late-stage clinical trials around the world

Woman speaking

2

New major acquisitions to broaden our reach

 

Man smiles in the workplace

76

Significant business development deals to enhance our pipeline

Woman MSD scientists in a lab
Our pipeline

We’re dedicated to translating breakthrough research into life-changing medicines and vaccines.

man and woman MSD scientists
Careers

Are you interested in a career in R&D? Join us to help address some of the world's most difficult challenges.

Health awareness

How we can strengthen vaccination programs and build vaccine confidence together

Two MSD leaders share how we’re working to help protect communities from vaccine-preventable illnesses

February 21, 2024

Share this article

.st0{fill:#00857C;}

article hero thumbnail

Vaccines are one of the most significant public health achievements in modern history, playing a vital role in helping to prevent certain infectious diseases and protect communities across the globe.

Unfortunately, the COVID-19 pandemic brought forth a new set of challenges in sustaining vaccination efforts for other preventable diseases — highlighting existing disparities and inequalities in access to health care and underscoring the urgent need for action.

In two op-eds for Devex, an independent news organization covering global development, Drew Otoo, Pharm.D., president of global vaccines, and Alfred Saah, M.D., executive director of scientific affairs, highlighted some of the ways we’re working to address these challenges at the global, national and local levels.

Collaborating to help increase health equity

Otoo said collaboration across sectors is key to building trust, enabling equity and establishing stronger, more resilient vaccination programs.

“Now more than ever, we have an opportunity to evaluate and strengthen our approach… Together, we can help create a more equitable future where vaccines are available to and accepted by all who can benefit from them.”

  • Drew Otoo, Pharm.D.
    President of global vaccines, MSD

Otoo shared examples of our work with local and global stakeholders to develop tailored approaches to improve vaccine confidence and supply vaccines for communities that might otherwise be without them:

  • Local organizations and community leaders have a deep understanding of the issues contributing to inequities and low routine vaccination rates in their communities, and they’re essential to identifying and executing solutions. We know this to be the case from our efforts through ImmUNITY Chicago, an initiative we helped catalyze with local stakeholders to address lower vaccination rates among neighborhoods in the Southwest Side of Chicago, predominantly among communities of color.
  • Strategic global collaborations are also critical to enabling stronger, more sustainable vaccination programs. We work with Gavi, the Vaccine Alliance — a global alliance that has helped to vaccinate nearly half of the world’s children in low-income countries.

Combating vaccine hesitancy and building trust

Saah emphasized our commitment to addressing vaccine hesitancy (the reluctance or refusal to vaccinate despite the availability of vaccines) and building confidence at local, national and global levels.

“By understanding the knowledge gaps and prioritizing strategies that strengthen how we communicate…we can potentially combat vaccine hesitancy, improve vaccine confidence and make a difference in global public health.”

  • Alfred Saah, M.D.
    Executive director of scientific affairs, MSD

Despite the well-documented benefits of vaccines, hesitancy is a longstanding public health issue that can result in under-vaccination and global disease outbreaks. The reasons behind vaccine hesitancy are often connected to the 3Cs Model, defined by a World Health Organization strategic advisory group:

  • Complacency: The perception that vaccine-preventable diseases pose little risk to individuals.
  • Convenience: The degree to which vaccination services are accessible.
  • Confidence: The degree to which an individual believes vaccines work, are safe and effective and are part of a trustworthy public health and medical system.

Saah shared some of our efforts to improve vaccine confidence, which include:

  • Working with collaborators to reach the global population and engage communities through mediums that resonate, such as social media, and through messages that can be delivered by trusted community members.
  • Building capabilities for our colleagues in local markets to better understand the strengths and vulnerabilities of vaccination programs on a global and national scale.

Continuing our work to improve vaccine access

Despite the challenges ahead, both Saah and Otoo are optimistic about the future.

“Combating vaccine hesitancy is not an easy feat and has been a challenge our global society has faced for centuries,” wrote Saah. “However, these challenges bring new opportunities to improve our approach and be better advocates for ourselves, our families and our communities.”

“By going where the need exists and continuing to invest in innovative, strategic and diverse collaborations, I'm confident we'll find new ways to solve complex public health problems.”

— Drew Otoo

Learn more about how collaborations can help yield stronger vaccination programs.